A Study to Compare Two Different Brain Imaging Techniques in Healthy Volunteers and in Schizophrenic Patients
Completed
- Conditions
- Schizophrenia
- Interventions
- Procedure: pet/spect scan
- Registration Number
- NCT00392743
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
A direct comparison of Positron Emission Tomography (PET) (11C-Raclopride) and Single Photon Emission Computed Tomography (SPECT) (123I-IBZM) D2 RO measurements would allow GSK to gain understanding on the SPECT results obtained with SB773812, and to accurately interpret future D2 RO results from either PET or SPECT studies with new compounds.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description pet/spect scan pet/spect scan -
- Primary Outcome Measures
Name Time Method PET and SPECT striatal binding potential at day 1
- Secondary Outcome Measures
Name Time Method plasma concentrations at the time of scanning, at day 1
Trial Locations
- Locations (1)
GSK Investigational Site
🇪🇸Sant Boi de Llobregat, Spain